Control Strategy Approach for a Well-Characterized Vaccine Drug Product

References

1. 1.↵
   International Conference on Harmonisation. Quality Guideline Q10: Pharmaceutical Quality System, 2008. ICH Web site. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf (accessed Aug 8, 2018).
2. 2.↵
   International Conference on Harmonisation. Quality Guideline Q9: Quality Risk Management, 2005. ICH Web site. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf (accessed Aug 8, 2018).
3. 3.↵
   International Conference on Harmonisation. Quality Guideline Q8(R2): Pharmaceutical Development, 2009. ICH Web site. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf (accessed Aug 8, 2018).
4. 4.↵
   International Conference on Harmonisation. Quality Guideline Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities), 2012. ICH Web site. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf (accessed Aug 8, 2018).
5. 5.↵
   1. Schiel J. E.,
   2. Davis D. L.,
   3. Borisov O. V.

   1. Flynn G. C.,
   2. Nyberg G. B.

   Using Quality by Design Principles in Setting a Control Strategy for Product Quality Attributes. In State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. Monoclonal Antibody Therapeutics: Structure, Function, and Regulatory Space; Schiel J. E., Davis D. L., Borisov O. V., Eds.; ACS Symposium Series 1176, American Chemical Society: Washington, DC, 2014, pp 117–150.
6. 6.↵
   1. Piriou J.,
   2. Elissondo B.,
   3. Hertschuh M.,
   4. Ollivier R.

   Control Strategy as the Keystone of the Product Lifecycle, from Product/Process Understanding to Continuous Process Verification and Improvement. Pharmaceutical Engineering 2012, 32 (1), 1–8.

   OpenUrl
7. 7.↵
   1. Sunasara K.,
   2. Cundy J.,
   3. Srinivasan S.,
   4. Evans B.,
   5. Sun W.,
   6. Cook S.,
   7. Bortell E.,
   8. Farley J.,
   9. Griffin D.,
   10. Bailey Piatchek M.,
   11. Arch-Douglas K.

   Bivalent rLP2086 (Trumenba®): Development of a Well-Characterized Vaccine through Commercialization. Vaccine 2018, 36 (22), 3180–3189.

   OpenUrl
8. 8.↵
   1. Luo Y.,
   2. Friese O. V.,
   3. Runnels H. A.,
   4. Khandke L.,
   5. Zlotnick G.,
   6. Aulabaugh A.,
   7. Gore T.,
   8. Vidunas E.,
   9. Raso S. W.,
   10. Novikova E.,
   11. Byrne E.,
   12. Schlittler M.,
   13. Stano D.,
   14. Dufield R. L.,
   15. Kumar S.,
   16. Anderson A. S.,
   17. Jansen K. U.,
   18. Rouse J. C.

   The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine against Meningococcal Meningitis B Disease. AAPS J. 2016, 18 (6), 1562–1575.

   OpenUrlCrossRef
9. 9.↵
   U.S. Food and Drug Administration. First Vaccine Approved by FDA to Prevent Serogroup B Meningococcal Disease, 2014. FDA Web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm420998.htm (accessed Aug 8, 2018).
10. 10.
    Australian Government Department of Health Therapeutic Goods Administration. Prescription Medicines: Registration of New Chemical Entities in Australia, 2017. TGA Web site. https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia (accessed Aug 8, 2018).
11. 11.
    Product Monograph: Trumenba. Pfizer Canada Inc; 2017. https://pdf.hres.ca/dpd_pm/00041515.PDF (accessed Aug 8, 2018).
12. 12.
    European Medicines Agency. EPAR Summary for the Public: Trumenba, 2017. EMA Web site. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004051/WC500228998.pdf (accessed Aug 8, 2018).